The brokerage believes consensus earnings estimates for the hospital sector have bottomed out, while valuations have moderated. It also expects the initial profitability pressure from the ongoing bed expansion cycle to be largely reflected in stock prices. Newly added capacity is ramping up at a healthy pace, supporting the earnings outlook.
The brokerage raised its price target for Max Healthcare to Rs 1,450 from Rs 825, implying an upside of around 33.32% from current levels. It favours the company for its disciplined capital allocation, stronger EBITDA growth outlook and more favourable capacity expansion trajectory.
Max Healthcare is expected to report a compound annual growth rate (CAGR) of 20% in revenue and 22% in EBITDA between FY26 and FY29.
The price target for Apollo Hospitals was increased to Rs 10,500 from Rs 6,230, indicating an upside of around 15.5% from current levels.
However, the brokerage flagged risks to the sector's outlook, including the possibility of the Supreme Court extending price caps beyond oncology drugs and a larger-than-expected profitability drag from newly commissioned hospitals.
For Max Healthcare, a higher share of institutional patients could dilute revenue per patient. For Apollo Hospitals, rising costs associated with its round-the-clock operations could constrain margin expansion in its HealthCo business.
Click here to visit SEBI Scores